Weekly shot could replace daily hormone injections for adults

NCT ID NCT01247675

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests a new once-weekly growth hormone injection (ACP-001) in adults with growth hormone deficiency. It compares three different doses of the weekly shot against a standard daily growth hormone product over four weeks. The goal is to see if the weekly injection is safe, well-tolerated, and produces similar drug levels in the body as the daily version.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ACP-001 (TransCon hGH)
What this could lead to
If successful, this could offer adults with growth hormone deficiency a more convenient once-weekly injection instead of daily shots.
What could go wrong
This is an early phase 2 study with only 37 participants over 4 weeks, so results may not apply to all patients. The weekly injection may not work as well as daily treatment or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT GROWTH HORMONE DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Aarhus University Hospital

    Aarhus, 8000, Denmark

  • Charité University Hospital Berlin

    Berlin, 12203, Germany

  • Karolinska University Hospital

    Stockholm, 17176, Sweden

  • University Hospital Genova

    Genova, 16132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.